Our Journey
1984
Incorporation of Neuland
1986
First API sale of salbutamol sulphate / albuterol sulphate
1994
Neuland goes public
1997
First US FDA audit
2004
Setting up of US Operations
2007
Setting up of Japan Subsidiary
2008
Separate R&D Centre established; EDQM audit of Unit 1
2009
PMDA, Japan approval First NCE approval
2013
Strategic alignment of business towards niche APIs & CMS
2015
10th US FDA audit
2016
R&D facility approved by US FDA
2017
Among first 3 API facilities in India to be audited by CFDA (Unit 1) EDQM Audit of Unit 2
2018
Acquisition of advanced intermediates & API facility
2019
Increased flow of projects from CMS Japan Active emphasis on supply chain de-risking
2020
₹100 Mn+ revenue 75+ live CMS Projects
2021
Unit 3 commercialisation
1984-2003
Laying Strong Foundation
2004-2013
Deepening our Capabilities
2013-Today
Increased Sustainable Growth
